- $1.52bn
- $1.20bn
- $411.33m
Brief: Innoviva Reports Second Quarter 2022 Financial Results And Highlights Recent Company Progress
Innoviva Inc reports results for the quarter ended in June - Earnings Summary
Innoviva Inc expected to post earnings of 33 cents a share - Earnings Preview
Brief: Innoviva Sells 15% Economic Stake In Theravance Respiratory Co To Royalty Pharma For Approximately $282 Mln Plus Full Ownership Of Existing Equity Investments, The Potential For $50 Mln Milestone Payment
La Jolla soars on takeover deal by Innoviva
Brief: Innoviva To Acquire La Jolla Pharmaceutical Co
Antibacterials developer Entasis surges on takeover by Innoviva
Brief: Innoviva To Acquire Entasis Therapeutics
Innoviva Inc reports results for the quarter ended in March - Earnings Summary
Brief: Innoviva Posts Quarterly EPS Of $0.20
Innoviva Inc expected to post earnings of 44 cents a share - Earnings Preview
Brief: Innoviva Prices Upsized Offering Of $225 Million Of 2.125% Convertible Senior Notes
Brief: Innoviva Announces Proposed Offering Of $200 Million Of Convertible Senior Notes
Innoviva Inc reports results for the quarter ended in December - Earnings Summary
Brief: Innoviva Reports Fourth Quarter 2021 Financial Results
Brief: Innoviva Submits Non-Binding Proposal To Acquire Of Entasis Therapeutics
Innoviva Inc expected to post earnings of 41 cents a share - Earnings Preview
Innoviva Inc reports results for the quarter ended in September - Earnings Summary
Brief: Innoviva Q3 EPS $0.90